Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Usana Health Sciences's Revenue for the
three
months ended in Mar. 2026 was $250.2 Mil. Usana Health Sciences's average Accounts Receivable for the
three
months ended in Mar. 2026 was $9.7 Mil.
Hence, Usana Health Sciences's Receivables Turnover for the
three
months ended in Mar. 2026 was 25.91.
Usana Health Sciences (NYSE:USNA) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Usana Health Sciences Receivables Turnover Related Terms
Usana Health Sciences Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Usana Health Sciences's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
USNA vs NATR, ENHA, BYND: Receivables Turnover Comparison
For the Packaged Foods subindustry, Usana Health Sciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Usana Health Sciences Receivables Turnover vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Usana Health Sciences's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Usana Health Sciences (USNA) has a Receivables Turnover of 25.91 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Usana Health Sciences and its competitors. According to the industry distribution chart, Usana Health Sciences ranks #64 out of 1946 companies in the Consumer Packaged Goods industry, placing it in the top 3.3%.
Is Usana Health Sciences' Receivables Turnover too high?
Usana Health Sciences' current Receivables Turnover is 25.91. The Consumer Packaged Goods industry median Receivables Turnover is 9.33. Usana Health Sciences' value of 25.91 is 177.7% above this industry median. Based on the distribution chart, Usana Health Sciences ranks #64 out of 1946 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Usana Health Sciences has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Usana Health Sciences' Receivables Turnover compare to NATR and ENHA?
According to the Consumer Packaged Goods industry distribution chart, Usana Health Sciences ranks #64 out of 1946 companies for Receivables Turnover. This places Usana Health Sciences in the top 3% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 9.33. Usana Health Sciences' value of 25.91 is 177.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Consumer Packaged Goods company?
The median Receivables Turnover among Consumer Packaged Goods companies is 9.33, based on 1,946 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Usana Health Sciences's current Receivables Turnover of 25.91 is 177.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Usana Health Sciences and its competitors. For the Consumer Packaged Goods industry, the median Receivables Turnover is 9.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Usana Health Sciences's current Receivables Turnover is 25.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Usana Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Usana Health Sciences (USNA) is currently considered Possible Value Trap. The stock's GF Value™ is $41.43, compared to a current price of $22.12 — trading 46.6% below its estimated fair value. The current Receivables Turnover is 25.91 and 177.7% above the Consumer Packaged Goods industry median of 9.33. Usana Health Sciences' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Usana Health Sciences (USNA), the current Receivables Turnover is 25.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Usana Health Sciences (USNA) Overvalued in 2026?
Based on GuruFocus' analysis, Usana Health Sciences stock appears to be undervalued.
The current stock price of $22.12 is trading 46.6% below its estimated GF Value™ of $41.43.
GuruFocus considers Usana Health Sciences to be Possible Value Trap.
Key valuation signals for USNA:
Receivables Turnover: 25.91
GF Value™: $41.43 vs. price of $22.12 (46.6% below fair value)
Industry Position: 177.7% above the Consumer Packaged Goods median (#64 of 1946)
No single metric tells the full story. See the USNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
66GF Score
Get the complete analysis for USNA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
USNA has been successfully added to your 
